Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-07 pm EST
2.040 USD   +0.99%
02/03Invivyd Announces Changes to Executive Team
GL
02/03Invivyd, Inc. Announces Executive Changes
CI
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

11/09/2022 | 07:03am EST

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT.

A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation.

About Invivyd
(Nasdaq: IVVD)
Invivyd, formerly Adagio Therapeutics (Nasdaq: ADGI), is a biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases.​ The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. ​Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape.​ The company’s integrated discovery platform is generating a robust pipeline of products for use in both prevention and treatment of disease. NVD200, Invivyd’s first antibody combination product candidate for the prevention and treatment of COVID-19, ​includes a re-engineered version of adintrevimab, an investigational monoclonal antibody which demonstrated clinically meaningful results against multiple variants of concern in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19, prior to the emergence of Omicron. The safety and efficacy of adintrevimab have not been established. The company also has multiple discovery stage candidates for the prevention of seasonal influenza. Visit www.invivyd.com to learn more.

Contacts
Media Contact:
Tony Berry, Evoke Canale
774-317-0422
anthony.berry@evokegroup.com

Investor Contact:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com


All news about INVIVYD, INC.
02/03Invivyd Announces Changes to Executive Team
GL
02/03Invivyd, Inc. Announces Executive Changes
CI
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
01/09Invivyd : J.P. Morgan 41st Annual Healthcare Conference
PU
01/09Invivyd, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
GL
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
AQ
2022Invivyd, Inc.(NasdaqGM:IVVD) added to NASDAQ Biotechnology Index
CI
2022Invivyd Names Jeremy Gowler as Chief Operating, Commercial Officer
MT
2022Invivyd, Inc. : Change in Directors or Principal Officers, Other Events, Financial Stateme..
AQ
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -238 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -0,93x
Yield 2022 -
Capitalization 222 M 222 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Last Close Price 2,04 $
Average target price 2,75 $
Spread / Average Target 34,8%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.34.67%220
REGENERON PHARMACEUTICALS, INC.8.54%83 397
VERTEX PHARMACEUTICALS4.24%78 258
WUXI APPTEC CO., LTD.13.21%39 435
BIONTECH SE-5.43%34 256
BEIGENE, LTD.11.48%25 531